Option Movers | Oracle Shows Bearish Sentiment; HIMS Put Contracts Surge about 300%!
Wall Street ended higher on Friday (Oct 17) as investors assessed U.S. President Donald Trump's latest remarks on China, while quarterly results from regional banks eased concerns about credit risks.
Regarding the options market, a total volume of 74,146,508 contracts was traded last Friday, call ratio accounted for 56%.
Top 10 Option Volumes
Top 10: $TSLA(TSLA)$; $NVDA(NVDA)$; $AMD(AMD)$; $AAPL(AAPL)$; $AMZN(AMZN)$; $INTC(INTC)$; $PLTR(PLTR)$; $MSTR(MSTR)$; $ORCL(ORCL)$; $HIMS(HIMS)$
Source: Tiger Trade App
$Oracle(ORCL)$ stock plunged about 7% last Friday, marking its largest single-day decline since January this year.
Oracle significantly raised its long-term financial guidance at AI World conference in Las Vegas, painting an enticing growth picture: by fiscal 2030, its cloud infrastructure revenue is projected to reach a staggering $166 billion (far exceeding the $18 billion target for fiscal 2026), adjusted earnings per share of $21, total revenue of $225 billion, and an annualized sales growth rate exceeding 31%. These figures suggest explosive growth in the coming years.
Wall Street analysts focused their firepower on Friday, sharply highlighting key unanswered questions behind Oracle's ambitious targets, particularly the source of massive funding required for this expansion.
A total number of 598.87K options related to $Oracle(ORCL)$ was traded last Friday. Based on option delta volume, traders sold a net equivalent of -1,047,366 shares of stock.
Source: Market Chameleon
Unusual Options Activity
Source: Market Chameleon
$Hims & Hers(HIMS)$ stock fell 15.8% last Friday after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease. Here’s what investors need to know.
While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and $Novo Nordisk(NVO)$’s Ozempic, it sells cheaper, compounded versions of them.
The company’s business model relies on offering more affordable alternatives to these high-demand drugs, and the prospect of the brand-name versions becoming significantly cheaper could negatively impact the company’s market share and profitability.
A total number of 533,841 options related to $HIMS(HIMS)$ was traded last Friday, 2.5 times higher than the 90-day average trading volume. Put options related to HIMS showed huge gains last Friday. For example, the $50 strike put option expiring Oct 24 soared 294.8%.
Source: Tiger Trade App
TOP Bullish & Bearish Single Stocks
This report shows stocks with the highest volume of bullish and bearish activity by option delta volume, which converts option volume to an equivalent stock volume (bought or sold).
If we take the total positive option delta volume and subtract the total negative option delta volume, we will get the net imbalance. If the net imbalance is positive, there is more bullish pressure. If the net is negative, there is more bearish pressure.
Top 10 bullish stocks: $AAPL(AAPL)$; $PFE(PFE)$; $GM(GM)$; $BAC(BAC)$; $WMT(WMT)$; $C(C)$; $HBAN(HBAN)$; $MRK(MRK)$; $GE(GE)$; $SBUX(SBUX)$
Top 10 bearish stocks: $ORCL(ORCL)$; $VZ(VZ)$; $FCX(FCX)$; $AMZN(AMZN)$; $BEN(BEN)$; $VST(VST)$; $QCOM(QCOM)$; $NEM(NEM)$; $MCHP(MCHP)$; $UNH(UNH)$
Source: Market Chameleon
If you are interested in options and you want to:
Share experiences and ideas on options trading.
Read options-related market updates/insights.
Learn more about options trading if you are a beginner in this field.
Please click to join Tiger Options Club
$(ORCL)$ $(HIMS)$Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
